{"protocolSection":{"identificationModule":{"nctId":"NCT06236750","orgStudyIdInfo":{"id":"EFJP001"},"organization":{"fullName":"MiMedx Group, Inc.","class":"INDUSTRY"},"briefTitle":"Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds","officialTitle":"A Post-Marketing Surveillance to Observe the Safety and Efficacy of Dehydrated Human Amnion/Chorion Membrane (DHACM) Wound Graft in the Management of Non-Ischemic Chronic Wounds"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-08-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-01-24","studyFirstSubmitQcDate":"2024-01-24","studyFirstPostDateStruct":{"date":"2024-02-01","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-24","lastUpdatePostDateStruct":{"date":"2024-02-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"MiMedx Group, Inc.","class":"INDUSTRY"},"collaborators":[{"name":"CMIC Co, Ltd. Japan","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.","detailedDescription":"The study will enroll 75 subjects diagnosed with intractable diabetic foot ulcers or venous leg ulcers at 5 plastic surgery sites in Japan. Subjects will be treated with weekly applications of EPIFIX for up to 12 weeks, followed by 6 months of follow-up."},"conditionsModule":{"conditions":["Diabetic Foot Ulcer","Venous Leg Ulcer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":75,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Patients with Non-Ischemic Chronic Wounds","type":"EXPERIMENTAL","description":"Patients with intractable diabetic foot ulcer or venous leg ulcer that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies.","interventionNames":["Device: EPIFIX"]}],"interventions":[{"type":"DEVICE","name":"EPIFIX","description":"EPIFIX® is an allograft derived from dehydrated human amnion/chorion membrane. EPIFIX is a medical device in Japan (Generic name: Material using human amniotic membrane for promotion of tissue healing) for use on intractable ulcers that are non-responsive to existing therapies for the purpose of promoting wound healing.","armGroupLabels":["Patients with Non-Ischemic Chronic Wounds"],"otherNames":["DHACM"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Efficacy Endpoint: Healing of Ulcers at 4 Weeks, 8 Weeks, and 12 Weeks","description":"The percentage of patients to achieve wound closure at 4 weeks, 8 weeks, and 12 weeks after initial DHACM application, as a measure of healing rate.","timeFrame":"4 weeks, 8 weeks, and 12 weeks after initial application"},{"measure":"Safety Endpoint: Incidence of Adverse Events","description":"Incidence rate of adverse events in DHACM-treated patients during 12 weeks of treatment and 6 months of follow-up.","timeFrame":"9 months after initial application"}],"otherOutcomes":[{"measure":"Efficacy Endpoint: Reduction in Wound Size at 4 Weeks, 8 Weeks, and 12 Weeks","description":"Wound size will be measured at 4 weeks, 8 weeks, and 12 weeks after initial DHACM application, and the percent reduction of wound area will be calculated compared to baseline (week 0), as a measure of rate of wound closure.","timeFrame":"4 weeks, 8 weeks, and 12 weeks after initial application"},{"measure":"Efficacy Endpoint: Time to Complete Wound Healing during 12 Weeks of Application","description":"The amount of time after initial DHACM application to achieve complete epithelialization of the wound.","timeFrame":"12 weeks after initial application"},{"measure":"Efficacy Endpoint: Wound Recurrence for 6 months after Wound Closure","description":"The recurrence rate of healed ulcers will be monitored for 6 months after wound closure is achieved.","timeFrame":"6 months after wound closure"},{"measure":"Safety Endpoint: Incidence of Device Deficiencies","description":"Incidence rate of device deficiencies, severity, and details in DHACM-treated patients during 12 weeks of treatment and 6 months of follow-up.","timeFrame":"9 months after initial application"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nPatients with intractable diabetic foot ulcers or venous leg ulcers that have not decreased in surface area by at least 50% after 4 weeks of conventional therapies, such as radical wound management (removal of necrotic tissue, infection control, wound cleansing, etc.), glycemic control for diabetic foot ulcers, compression therapy for venous stasis ulcers and moist therapy using wound dressing materials.\n\nExclusion Criteria:\n\n1. Areas of active infection or latent infection.\n2. Patients with disorders that would cause an intolerable risk of postoperative complications.\n3. Ulcers that cannot be sufficiently debrided.\n4. Ulcers that, after debridement, have blood flow disorders where wound bed necrosis progresses at an early stage.\n5. Wound surfaces with multiple ulcer surfaces and exposed bone, and no blood flow in the wound bed.\n6. Patients with hypersensitivity to the aminoglycoside antibiotics used during manufacturing.","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Chief Medical Officer","role":"CONTACT","phone":"770-651-9100","email":"CTInquiries@mimedx.com"}],"overallOfficials":[{"name":"David Mason, MD","affiliation":"MiMedx Group, Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Kobe University Hospital","status":"RECRUITING","city":"Kobe","state":"Hyōgo","zip":"650-0017","country":"Japan","geoPoint":{"lat":34.6913,"lon":135.183}},{"facility":"Saitame Medical University Hospital","status":"RECRUITING","city":"Iruma-gun","state":"Saitama","zip":"350-0495","country":"Japan"},{"facility":"Juntendo University Hospital","status":"RECRUITING","city":"Bunkyō-Ku","state":"Tokyo","zip":"113-8431","country":"Japan"},{"facility":"Kyorin University Hospital","status":"RECRUITING","city":"Mitaka-shi","state":"Tokyo","zip":"181-8611","country":"Japan"},{"facility":"Tokyo Medical University Hospital","status":"RECRUITING","city":"Shinjuku-Ku","state":"Tokyo","zip":"160-0023","country":"Japan"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D017719","term":"Diabetic Foot"},{"id":"D014647","term":"Varicose Ulcer"}],"ancestors":[{"id":"D003925","term":"Diabetic Angiopathies"},{"id":"D014652","term":"Vascular Diseases"},{"id":"D002318","term":"Cardiovascular Diseases"},{"id":"D016523","term":"Foot Ulcer"},{"id":"D007871","term":"Leg Ulcer"},{"id":"D012883","term":"Skin Ulcer"},{"id":"D012871","term":"Skin Diseases"},{"id":"D017437","term":"Skin and Connective Tissue Diseases"},{"id":"D048909","term":"Diabetes Complications"},{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D003929","term":"Diabetic Neuropathies"},{"id":"D014648","term":"Varicose Veins"}]}},"hasResults":false}